A clinical trial to investigate AZD-9150 (ISIS-STAT3-2.5Rx) in combination with durvalumab (MEDI-4736)-Trial 2

Trial Profile

A clinical trial to investigate AZD-9150 (ISIS-STAT3-2.5Rx) in combination with durvalumab (MEDI-4736)-Trial 2

Planning
Phase of Trial: Phase II

Latest Information Update: 07 May 2015

At a glance

  • Drugs AZD 9150 (Primary) ; Durvalumab
  • Indications Cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 May 2015 Assumed indication as cancer because the MR does not specify the indication. Also, the MR states that the company is planning to initiate 2 trials evaluating this combination. So, I have created this and another identical CTP 256663.
    • 07 May 2015 New trial record
    • 05 May 2015 According to an AstraZeneca media release, the company plans to initiate two clinical studies evaluating ISIS-STAT3-2.5Rx in combination with MEDI4736 in 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top